Clinical implication of cellular vaccine in glioma: current advances and future prospects.

摘要: Gliomas, especially glioblastomas, represent one of the most aggressive and difficult-to-treat human brain tumors. In last few decades, clinical immunotherapy has been developed provided exceptional achievements in checkpoint inhibitors vaccines for cancer treatment. Immunization with cellular advantage containing specific antigens acceptable safety to potentially improve therapy. Based on T cells, dendritic cells (DC), tumor natural killer feasibility have validated trials glioma For TAA engineered therapy mainly uses chimeric antigen receptors (IL13Rα2, EGFRvIII HER2) DNA methylation-induced technology (CT antigen) activate immune response. Autologous cells/tumor vaccine (ADCTA) pulsed lysate peptides elicit antigen-specific cytotoxic cell responses patients malignant gliomas, while its pro-survival effect is biased. Vaccinations using autologous modified TAAs or fusion fibroblast are characterized by both effective humoral cell-mediated immunity. Even though therapeutic effects observed, this showed feasibility, asking larger cohort studies better guidelines optimize efficiency anti-glioma